AVROBIO Inc. (AVRO) deprioritizing its Fabry disease program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Avrobio Inc. (AVRO) PT Lowered to $6 at Mizuho Securities
January 5, 2022 5:28 PM ESTMizuho Securities analyst Uy Ear lowered the price target on Avrobio Inc. (NASDAQ: AVRO) to $6.00 (from $28.00) while maintaining a Buy rating.
The analyst commented, "The new clinical data from the Fabry program is disappointing. We update our model to exclude our sales and... More
AVROBIO's (AVRO) Focus Shift is Disappointing, But Logical, Outlook is Cautions - Stifel
January 4, 2022 10:37 AM ESTStifel analyst Dae Gon Ha maintains a "Hold" rating on shares of AVROBIO Inc. (NASDAQ: AVRO), following news that company is shifting its portfolio... More
AVROBIO Inc. (AVRO) Halted, News Pending
January 4, 2022 6:55 AM ESTAVROBIO Inc. (NASDAQ: AVRO) Halted, News Pending
